Docoit

Analysis of Research Paper Report HCS/438 Statistical Applications University of Phoenix Analysis of Research Paper Report In this paper, I will interpret the statistical significance of a study. The following points will be addressed; 1) statistical procedures mentioned in the study, 2) conclusions reached by the study, 3) determine if the conclusions are appropriate, 4) determine if the findings are statistically significant, 5) describe the process that I used to make this determination and 6) provide the level of significance. The article that I chose for this research paper is from the PfizerPro website in regards to the heart medication called LIPITOR. LIPITOR is medication designed to lower and individual’s LDL cholesterol for the prevention of heart disease. There are several statistical procedures mentioned in this study that discusses the effects of LIPITOR on non-fatal and fatal coronary heart disease within certain age groups of men but I will only cover two of this in this paper. The study also discusses the following, “1) the effect of LIPITOR 10 mg/day on non-fatal myocardial infarction or coronary heart disease death, 2) the effect of LIPITOR 10 mg/day of an occurrence of major cardiovascular event, 3) the effect of LIPITOR 80 mg/day vs. 10 mg/day on time to occurrence of major cardiovascular events” (“Prevention of Cardiovascular Disease,” 2010, p. 1). The conclusions that the study reached that LIPITOR was effective in reducing the rate of coronary events (either fatal or non-fatal). To elaborate on this, LIPITOR was effective in the prevention of myocardial fraction events regardless of the baseline LDL (Low-density lipoprotein). The conclusions are appropriate based on the figures given in the article for example, “LIPITOR also significantly decreased the relative risk for revascularization procedures by 42%. Although the reduction of fatal and non-fatal strokes did not reach a pre-defined significance level (p=0.01), a favorable trend was observed with a 26% relative risk reduction (incidences of 1.7% for LIPITOR and 2.3% for placebo). There was no significant difference between the treatment groups for death due to cardiovascular causes (p=0.51) or non-cardiovascular causes (p=0.17) (“Prevention of Cardiovascular Disease,” 2010). By looking at the results of LIPTOR in the study, it shows the overall effectiveness of the drug. The findings for LIPITOR were significant because of the many types of clinical trials use to gather the information needed to complete the study before the drug was put on the market. For example, in study #2 (Effect of LIPITOR 10 mg/day on occurrence of major cardiovascular event (myocardial infarction, acute CHD death, unstable angina, coronary revascularization, or stroke) versus Study #1 mentioned in the previous paragraph, this is the result of the two trials: “Treatment with LIPITOR 80 mg/day significantly reduced the rate of MCVE (434 events in the 80 mg/day group vs. 548 events in the 10 mg/day group) with a relative risk reduction of 22%, HR 0.78, 95% CI (0.69, 0.89), p=0.0002” (“Prevention of Cardiovascular Disease,” 2010). In conclusion, the entire clinical study for LIPITOR was deemed a success based on the findings in the multiple studies performed on various subjects. But one question remains even with the success of the study, is it possible for the creators of LIPITOR to continue more studies to reach a final conclusion or will the studies that have been conducted prior to the release of this drug be sufficient' Reference: Prevention of Cardiovascular Disease. (2010). LIPITOR® (atorvastatin calcium) Tablets Clinical Studies, (), 1. Retrieved from https://www.pfizerpro.com/sites/ppro/Pages/product_info/lipitor_pi_clinical_studies.aspx